ArticlePeerJ2025
Mito-fission gene prognostic model for colorectal cancer.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dysregulated cellular metabolism is one of the major causes of colorectal cancer (CRC), including mitochondrial fission. Therefore, this study focuses on the specific regulatory mechanisms of mitochondrial dysfunction on CRC, which will provide theoretical guidance for CRC in the future. Methods: The Cancer Genome Atlas (TCGA)-CRC dataset, GSE103479 dataset and 40 mitochondrial fission-related genes (MFRGs) were downloaded in this study. The differentially expressed genes (DEGs) were analyzed in TCGA-CRC samples. Using MFRGs scores as traits, key module genes associated with its scores were screened by weighted gene co-expression network analysis (WGCNA). Then, differentially expressed MFRGs (DE-MFRGs) were obtained by intersecting DEGs and key module genes. Next, DE-MFRGs were subjected to univariate Cox, least absolute shrinkage and selection operator (LASSO), multivariate Cox and stepwise regression analysis to scree hub genes and to construct the risk model. The risk model was validated in GSE103479. Finally, the hub genes were comprehensively investigated through a multi-faceted approach encompassing clinical characteristic analysis, Gene Set Enrichment Analysis (GSEA), immune infiltration analysis, and drug sensitivity prediction. Subsequently, the expression levels of the identified key genes were validated utilizing quantitative real-time fluorescence PCR (qRT-PCR), reinforcing the findings and ensuring their accuracy. Results: The 49 DE-MFRGs were gained by intersecting 3,310 DEGs and 1,952 key module genes. Then, Conclusion: In this study, we found
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.